Extended Data Fig. 7: Association of clinical response with survival.

a, A two-tailed, Spearman correlation between positive epitopes versus the total number of neoantigens included in each patient’s PTCV. b, Interquartile survival analysis by magnitude (best response post-PTCV; IFNγ SFU) of evaluable patients. Six patients per group; Log-rank (Mantel-Cox) test. c, T cell reactivity evaluated by IFNγ-ELISpot stratified by responder or non-responder groups. Symbols represent individual patients (CR/PR, n = 6; SD/PD, n = 15 per group), the box extends from the 25th to the 75th percentile, the line inside the box is the median, and the whiskers extend from the minimum to maximum values. Significance was tested by a two-tailed, Mann-Whitney statistical analysis. d, Cumulative number of targetable neoantigens encoded in the vaccines of the 22 pts whose samples were evaluated by IFNγ ELISpot assay. The neoantigens are stratified by the predicted MHC Class I binding affinity as high (< 500 nM), medium (500–1000nM), and low (1000–2000 nM). While the majority of the neoantigens encoded in the PTCVs were categorized as high-affinity antigens, the medium and low-affinity antigens also yielded positive responses in a similar proportion.